www.sigmadesigns.com/news/sigma-designs-announces-plan-initial-distribution-6-00-per-share-shareholders-connection-voluntary-plan-liquidation-dissolution

This distribution will be made in accordance with the Company's previously ... customers, or other parties, the Company's ability to defend and settle those claims ...

www.sigmadesigns.com/news/sigma-designs-inc-announces-voluntary-delisting-nasdaq

Aug 3, 2018 ... 03, 2018 (GLOBE NEWSWIRE) — Sigma Designs, Inc.® (NASDAQ: ... Sigma expects to file the Form 25 on or about August 15, 2018 and ...

www.sigmadesigns.com/news/sigma-designs-inc-announces-plan-sell-z-wave-business-240-million

Jan 23, 2018 ... 23, 2018 – Sigma Designs, Inc.® (NASDAQ: SIGM) today announced that ... as to the ultimate amounts to be distributed or the timing of any distributions. .... and the record dates for all distributions to be made to shareholders.

www.ncbi.nlm.nih.gov/pmc/articles/PMC6485085

Apr 26, 2019 ... Furthermore, vaccine formulations have not been studied or optimized with ... within various formulation designs with other adjuvants / delivery systems in ... using 100 kDa MWCO amicon centrifuge tubes (Sigma Aldrich). ..... Daniel E. Speiser ... Zeltins A, West J, Zabel F, El Turabi A, Balke I, Haas S, et al.

www.sciencedirect.com/science/article/pii/S221112471930484X

Apr 30, 2019 ... Called atypical MBCs (atMBCs) or exhausted or tissue-like B cells, they ... expression patterns resemble those of human FCRL3 (Li et al., 2014). ..... could be subdivided into CD138int cells that co-expressed FCRL5, ..... OVA (Sigma), and LCMV Glycoprotein (kind gift of J. Teijaro). ..... Speiser et al., 2014.

www.ncbi.nlm.nih.gov/pmc/articles/PMC5019125

During persistent immune activation, such as uncontrolled tumor growth or chronic ... Dysfunctional CD8+ T cells from LCMV infected mice (Blackburn et al., 2009; ... Indeed, therapeutic targeting of co-inhibitory receptors, such as CTLA-4 and .... gene expression patterns across the cell populations (Figure 1B, Figure S1).

www.ncbi.nlm.nih.gov/pmc/articles/PMC6355189

Numerous immune checkpoints (either coinhibitory or costimulatory) have been ..... Isotope Laboratories, Inc.), and pH was adjusted using DCl (Sigma) to 2.4 for stop ..... Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, et al . ..... Olive D, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S.

opticsoflife.org/pdfs/pubs/speiser%20et%20al%202011.pdf

Apr 14, 2011 ... Daniel I. Speiser,1,* Douglas J. Eernisse,2 and Sö nke Johnsen1 ... all biological lenses, or from some other material [4]. Elec- ..... by a Sigma Xi Grant-in-Aid of Research (G20071061856267476) awarded to D.I.S. .... issue of Current Biology, Speiser et al. ... of 'one-off ' eye designs of impressive diversity.

www.nature.com/articles/onc201735.pdf?origin=ppub

Mar 6, 2017 ... precautions must be implemented when designing combinatorial approaches for cancer treatment, because ... and patient samples, we and others have demonstrated a ... immunotherapy.3–6 For example, co-administration of a selective .... When administered as a single agent, BRAF inhibitors20 or CpG.